IO Therapy in mCRPC and Clinical Pearls

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Related Videos
Yuan Yuan, MD, PhD
Jeffery Zonder, MD
David R. Wise, MD, PhD
Andrew J. Armstrong, MD, MSc
Benjamin V. Stone, MD
Scott Tagawa, MD, MS, FACP
Expert on RCC
Experts on DTC
Experts on DTC
Expert on RCC
Related Content